新辅助化疗联合肿瘤细胞减灭术治疗38例晚期上皮性卵巢癌临床分析
Clinical analysis of 38 cases of advanced epithelial ovarian cancer treated by neoadjuvant chemotherapy combined with cytoreductive surgery
张梦捷 1董学彩 1张林方2
作者信息
- 1. 新乡市中心医院 妇瘤科,新乡医学院第四临床学院,河南 新乡 453000
- 2. 昆山市第四人民医院 急诊危重医学科,江苏 昆山 215300
- 折叠
摘要
[背景]观察新辅助化疗联合肿瘤细胞减灭术治疗晚期上皮性卵巢癌的效果及安全性.[病例报告]选择2015年4月26日至2016年4月26日间收治的76例晚期上皮性卵巢癌患者作为研究对象,按照就诊顺序随机分为对照组和观察组,每组各38例.对照组给予肿瘤细胞减灭术治疗,观察组给予新辅助化疗联合肿瘤细胞减灭术治疗,比较两组患者治疗方式的临床疗效和安全性.结果见,观察组患者治疗缓解率为71.1%,明显高于对照组的42.1%(P＜0.05),但观察组患者中、重度不良反应发生率明显高于对照组(P＜0.05).[讨论]采用新辅助化疗联合肿瘤细胞减灭术治疗晚期上皮性卵巢癌可提高疗效,但不良反应发生率较高.
Abstract
BACKGROUND To observe the efficacy and safety of neoadjuvant chemotherapy combined with cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.CASE REPORTS A total of 76 patients with advanced epithelial ovarian cancer admitted from April 26,2015 to April 26,2016 were selected as the study subjects and randomly divided into control group and observation group,with 38 patients in each group.The control group was treated with cytoreductive surgery,while the observation group was treated with neoadjuvant chemotherapy combined with cytoreductive surgery.The clinical efficacy and safety of the treatment methods were compared between the two groups.The results showed that the remission rate of patients in the observation group was 71.1%,which was significantly higher than 42.1%of patients in the control group(P＜0.05).But the incidence of moderate and severe adverse reactions in observation group was significantly higher than that of control group(P＜0.05).DISCUSSION Neoadjuvant chemotherapy combined with cytoreductive surgery in the treatment of advanced epithelial ovarian cancer can improve the efficacy,but the incidence of adverse reactions is higher.
关键词
上皮性卵巢癌/新辅助化疗/肿瘤细胞减灭术/安全性Key words
epithelial ovarian cancer/neoadjuvant chemotherapy/cytoreductive surgery/security引用本文复制引用
出版年
2024
NETL
NSTL
万方数据